var data={"title":"Promethazine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Promethazine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6848?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=promethazine-drug-information\" class=\"drug drug_general\">see &quot;Promethazine: Drug information&quot;</a> and <a href=\"topic.htm?path=promethazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Promethazine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709344\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Respiratory depression - Pediatrics:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Promethazine should not be used in pediatric patients younger than 2 years because of the potential for fatal respiratory depression.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing cases of respiratory depression, including fatalities, have been reported with the use of promethazine in pediatric patients younger than 2 years. A wide range of weight-based doses of promethazine have resulted in respiratory depression in these patients.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exercise caution when administering promethazine to pediatric patients 2 years and older. It is recommended that the lowest effective dose of promethazine be used in pediatric patients 2 years and older and that coadministration with other drugs with respiratory-depressant effects be avoided.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe tissue injury, including gangrene (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Promethazine can cause severe chemical irritation and damage to tissues regardless of the route of administration. Irritation and damage can result from perivascular extravasation, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis, and gangrene. In some cases, surgical intervention, including fasciotomy, skin graft, and/or amputation have been required.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Due to the risks of intravenous (IV) injection, the preferred route of administration of promethazine is deep intramuscular (IM) injection. Subcutaneous injection is contraindicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214081\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Phenadoz;</li>\n      <li>Phenergan;</li>\n      <li>Promethegan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214082\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bioniche Promethazine;</li>\n      <li>Histantil;</li>\n      <li>Phenergan;</li>\n      <li>PMS-Promethazine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061413\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Phenothiazine Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061406\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=promethazine-drug-information\" class=\"drug drug_general\">see &quot;Promethazine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Note:</b> Use with extreme caution utilizing the lowest most effective dose: Use has generally been replaced by agents that are more effective with fewer adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Allergic conditions; treatment:</b> Children &ge;2 years and Adolescents: Limited data available: Oral: 0.125 mg/kg/dose (maximum dose: 12.5 mg/dose) every 6 hours as needed during the day and 0.5 mg/kg/dose (maximum dose: 25 mg/dose) at bedtime as needed. <b>Note:</b> Not typically a first-line option for allergic conditions; other agents may be more effective with fewer adverse effects. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Nausea and vomiting:</b> Children &ge;2 years and Adolescents: Oral, IM, IV, rectal: 0.25 to 1 mg/kg/dose every 4 to 6 hours as needed (Kliegman 2007); maximum dose: 25 mg/dose. <b>Note:</b> Expert recommendations for postoperative nausea and vomiting (PONV) management do not include promethazine as an option for the prevention or treatment of PONV in pediatric patients; use replaced by newer agents (SAA [Gan 2014]; WHO 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Motion sickness:</b> Children &ge;2 years and Adolescents: Oral, rectal: 0.5 mg/kg 30 minutes to 1 hour before departure, then every 12 hours as needed (Kliegman 2007); maximum dose: 25 mg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Surgical analgesia/hypnotic; pre-/postoperative adjunct:</b> Children &ge;2 years and Adolescents: IM, IV: 0.25 to 1.1 mg/kg once in combination with an analgesic or hypnotic (at reduced dosage; low end of range) and with an atropine-like agent (at appropriate dosage) (Kliegman 2007). Promethazine dosage should not exceed 12.5 to 25 mg (ie, half of suggested adult dosage). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Allergic conditions: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral, rectal: 25 mg at bedtime <b>or</b> 12.5 mg before meals and at bedtime (range: 6.25 to 12.5 mg 3 times daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM, IV: 25 mg, may repeat in 2 hours when necessary; switch to oral route as soon as feasible </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Antiemetic:</b> Oral, IM, IV, rectal: 12.5 to 25 mg every 4 to 6 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Motion sickness:</b> Oral, rectal: 25 mg 30 to 60 minutes before departure, repeat 8 to 12 hours later as needed; maintenance: 25 mg twice daily  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Obstetrics (labor) analgesia adjunct:</b> IM, IV: Early labor: 50 mg; established labor: 25 to 75 mg in combination with analgesic at reduced dosage; may repeat every 4 hours for up to 2 additional doses (maximum: 100 mg/day while in labor)  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pre-/postoperative analgesia/hypnotic adjunct:</b> IM, IV: 25 to 50 mg in combination with analgesic or hypnotic (at reduced dosage)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Sedation:</b> Oral, IM, IV, rectal: 25 to 50 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;2 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge; 2 years and Adolescents: The manufacturer recommends to avoid use in pediatric patients with signs and symptoms of hepatic disease (extrapyramidal symptoms caused by promethazine may be confused with CNS signs of hepatic disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: There are no dosage adjustments provided in manufacturer's labeling; use with caution (cholestatic jaundice has been reported with use).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214053\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenergan: 50 mg/mL (1 mL) [contains edetate disodium, phenol, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenergan: 25 mg/mL (1 mL) [pyrogen free; contains edetate disodium, phenol, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (1 mL); 50 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6.25 mg/5 mL (118 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Rectal, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenadoz: 12.5 mg (12 ea); 25 mg (12 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phenergan: 12.5 mg (12 ea); 25 mg (12 ea); 50 mg (12 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Promethegan: 12.5 mg (12 ea); 25 mg (12 ea, 1000 ea); 50 mg (12 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg (1 ea, 12 ea); 25 mg (1 ea, 12 ea); 50 mg (12 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6.25 mg/5 mL (118 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg, 25 mg, 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214037\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061417\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food, water, or milk to decrease GI distress. Measure and administer prescribed dose of oral solution using dosing syringe, dosing spoon, or dosing cup. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Not for SubQ administration; promethazine is a chemical irritant which may produce necrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Preferred route of administration; administer as a deep IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: IV use should be avoided when possible since severe tissue damage has occurred with IV administration; in selected patients, promethazine has been diluted and infused at a maximum rate of 25 mg/minute. To minimize phlebitis, consider administering over 10 to 15 minutes, limiting initial dose to <sup>1</sup>/<sub>4</sub> or <sup>1</sup>/<sub>2</sub> the usual dose (eg, in adults 6.25 to 12.5 mg), further diluting the 25 mg/mL strength in 10 to 20 mL NS, and administering through a large bore vein (not hand or wrist) or via a running IV line at port farthest from patient's vein (ISMP 2006). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Discontinue immediately if burning or pain occurs with administration; evaluate for inadvertent arterial injection or extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses (Hurst 2004). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214074\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, oral solution, tablets: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppositories: Store refrigerated between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061416\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of perennial and seasonal allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis due to inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermographism; anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled; prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery; active treatment and prophylaxis of motion sickness; adjunctive therapy with analgesics and/or anesthesia for postoperative management; preoperative and postoperative sedation (including obstetrics); relief of apprehension and production of light sleep from which the patient can be easily aroused (All indications: FDA approved in ages &ge;2 years and adults) </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Anaphylaxis guidelines do not include promethazine as adjunctive therapy option; use should be avoided in this situation (AAAAI [Campbell 2014]; WAO [Simons 2013]). Postoperative nausea and vomiting (PONV) guidelines do not include promethazine as an option for the prevention or treatment of PONV in pediatric patients (SAA [Gan 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214135\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Promethazine may be confused with chlorproMAZINE, predniSONE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Phenergan may be confused with PHENobarbital, Phrenilin, Theragran</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric patients: High-risk medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Promethazine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Promethazine, as a single agent or as part of a combination, is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">To prevent or minimize tissue damage during IV administration, the Institute for Safe Medication Practices (ISMP) has the following recommendations:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Limit concentration available to the 25 mg/mL product</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Consider limiting initial doses to 6.25 to 12.5 mg</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Further dilute the 25 mg/mL strength into 10 to 20 mL NS</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Administer through a large bore vein (not hand or wrist)</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Administer via running IV line at port farthest from patient's vein</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Consider administering over 10 to 15 minutes</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">- Instruct patients to report immediately signs of pain or burning</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sominex: Brand name for promethazine in Great Britain, but also is a brand name for diphenhydrAMINE in the US</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214131\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, ECG changes (nonspecific QT changes) hypertension, hypotension, local thrombophlebitis, localized phlebitis, orthostatic hypotension, tachycardia, vasospasm (distal to injection site), venous thrombosis (local)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, akathisia, ataxia, catatonia, confusion, delirium, disorientation, dizziness, drowsiness, dystonia, euphoria, excitement, extrapyramidal reaction, fatigue, hallucination, hysteria, insomnia, lassitude, paralysis (local), Parkinsonian-like syndrome, tardive dyskinesia, nervousness, neuroleptic malignant syndrome, nightmares, sedation, seizure, sensory disturbance (local sensory loss)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis, gangrene of skin or other tissue (local), skin photosensitivity, skin pigmentation (slate gray), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, gynecomastia, hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast engorgement, ejaculatory disorder, impotence, lactation, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, immune thrombocytopenia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Abscess at injection site, injection site reaction (burning sensation at injection site, edema at injection site, erythema at injection site, pain at injection site), local tissue necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, corneal changes, diplopia, epithelial keratopathy, lens disease (changes), retinitis pigmentosa</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, asthma, nasal congestion, respiratory depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214059\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity or idiosyncratic reaction to promethazine, other phenothiazines, or any component of the formulation; coma; treatment of lower respiratory tract symptoms, including asthma; children &lt;2 years of age; intra-arterial or subcutaneous administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214041\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, pyloroduodenal obstruction, urinary retention, bladder neck obstruction, BPH, xerostomia, or visual problems.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: May cause photosensitivity; avoid prolonged sun exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Serious tissue injury: <b>[US Boxed Warning]: Promethazine injection can cause severe tissue injury (including gangrene) regardless of the route of administration. Tissue irritation and damage may result from perivascular extravasation, unintentional intra-arterial administration, and intraneuronal or perineuronal infiltration. In addition to gangrene, adverse events reported include tissue necrosis, abscesses, burning, pain, erythema, edema, severe spasm of distal vessels, phlebitis, thrombophlebitis, venous thrombosis, sensory loss, paralysis, and palsies. Surgical intervention including fasciotomy, skin graft, and/or amputation have been necessary in some cases. The preferred route of administration is by deep intramuscular (IM) injection.  Subcutaneous administration is contraindicated. Discontinue intravenous injection immediately with onset of burning and/or pain and evaluate for arterial injection or perivascular extravasation. Although there is no proven successful management of unintentional intra-arterial injection or perivascular extravasation, sympathetic block and heparinization have been used in the acute management of unintentional intra-arterial injection based on results from animal studies.</b>  Vesicant; for IV administration (<b>not</b> the preferred route of administration), ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression; leukopenia and agranulocytosis have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; cholestatic jaundice has been reported with use. Avoid use in pediatric patients with signs and symptoms of hepatic disease (extrapyramidal symptoms caused by promethazine may be confused with CNS signs of hepatic disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; may have increased risk of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Avoid use in patients with compromised respiratory function or in patients at risk for respiratory failure (eg, COPD, sleep apnea); may lead to potentially fatal respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: <b>[US Boxed Warning]: Respiratory depression, including fatalities, have been reported in children &lt;2 years of age. Use contraindicated in children &lt;2 years. In children &ge;2 years, use the lowest possible dose; other drugs with respiratory depressant effects should be avoided. </b> Antiemetics are not recommended for the treatment of uncomplicated vomiting in pediatric patients; limit use to prolonged vomiting of known etiology. Avoid use in children who may have Reye syndrome or hepatic disease as adverse reactions caused by promethazine may be confused with signs of primary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse  (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium metabisulfite: Injection may contain sodium metabisulfite; may cause allergic reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26080215\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Children with dehydration are at increased risk for development of dystonic reactions from promethazine. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214122\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214046\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12735&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Promethazine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Nasal): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Oral Inhalation): Promethazine may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epinephrine (Racemic): Promethazine may diminish the vasoconstricting effect of Epinephrine (Racemic).  Management: Monitor for diminished vasoconstrictive effects of racemic epinephrine (e.g., diminished efficacy when used for gingival retraction).  This interaction is likely of less concern in patients receiving epinephrine for other purposes (e.g., bronchodilation).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Systemic): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Systemic).  Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Promethazine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Promethazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214049\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214062\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Promethazine crosses the placenta (Potts 1961). Platelet aggregation may be inhibited in newborns following maternal use of promethazine within 2 weeks of delivery. Promethazine is approved for use as an antiemetic; however, other agents are recommended as initial therapy for the treatment of nausea and vomiting of pregnancy (ACOG 2015). Promethazine is indicated for use during labor for obstetric sedation and may be used alone or as an adjunct to opioid analgesics. Although promethazine is approved for the treatment of allergic conditions (eg, allergic rhinitis, urticaria), other agents are preferred for use in pregnant women (Scadding 2008; Wallace 2008; Zuberbier 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10483604\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Relief of symptoms, mental status and CNS effects (including sedation, akathisia, delirium, extrapyramidal symptoms); monitor for signs and symptoms of tissue injury (burning or pain at injection site, phlebitis, edema) with IV administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214040\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Phenothiazine derivative; blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; competes with histamine for the H<sub>1</sub>-receptor; muscarinic-blocking effect may be responsible for antiemetic activity; reduces stimuli to the brainstem reticular system </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214058\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral, IM: ~20 minutes; IV: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Usually 4 to 6 hours (up to 12 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid and complete; large first pass effect limits systemic bioavailability (Sharma  2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 13.4 &plusmn; 3.6 L/kg (Brunton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 93% (Brunton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; hydroxylation via CYP2D6 and N-demethylation via CYP2B6; significant first-pass effect (Sharma  2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: ~25% (Sharma 2003); Rectal: 21.7% to 23.4% (Brunton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IM: ~10 hours; IV: 9 to 16 hours; Suppositories, syrup: 16 to 19 hours (range: 4 to 34 hours) (Strenkoski-Nox 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to maximum serum concentration (Brunton 2011): Oral (syrup): 2.8 &plusmn; 1.4 hours; Rectal: 8.2 &plusmn; 3.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine, feces as inactive metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214061\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phenergan Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (1 mL): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $5.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Promethazine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (1 mL): $2.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $4.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Phenadoz Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (12): $212.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (12): $212.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Phenergan Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (12): $283.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (12): $283.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (12): $778.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Promethazine HCl Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (12): $212.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (12): $212.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (12): $566.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Promethegan Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (12): $212.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (12): $212.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (12): $429.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Promethazine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg/5 mL (473 mL): $22.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Promethazine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $49.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $50.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $77.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038783\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allerfen (IT);</li>\n      <li>Allergin (BD);</li>\n      <li>Allersoothe (AU, NZ);</li>\n      <li>Antiallersin (BG);</li>\n      <li>Atosil (DE);</li>\n      <li>Avomine (MT, TR);</li>\n      <li>Diphergan (PL);</li>\n      <li>Duplamin (IT);</li>\n      <li>Fargan (IT);</li>\n      <li>Farganesse (IT);</li>\n      <li>Fenazil (IT);</li>\n      <li>Fenazine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Fenergan (AR, ES, PE, PT, PY, UY, VE);</li>\n      <li>Hibechin (JP);</li>\n      <li>Hiberna (JP);</li>\n      <li>Himazin (KR);</li>\n      <li>Histaloc (AE, BH, KW, QA, SA);</li>\n      <li>Histazan (JO);</li>\n      <li>Histazin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Histin (BD);</li>\n      <li>Lergigan (SE);</li>\n      <li>Meta (TH);</li>\n      <li>Montil (BD);</li>\n      <li>Phenergan (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, DK, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, IE, IN, IQ, IR, IS, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PK, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Phenerzin (PH);</li>\n      <li>Pipolfen (UA);</li>\n      <li>Pipolphen (HN, HU, VN);</li>\n      <li>Profergan (BR);</li>\n      <li>Progic (BD);</li>\n      <li>Prome (ID);</li>\n      <li>Promeright (LK);</li>\n      <li>Promet (JO, PH);</li>\n      <li>Prometazina (IT);</li>\n      <li>Prometazina Cloridrato (IT);</li>\n      <li>Prometin (QA);</li>\n      <li>Promezine (MY);</li>\n      <li>Proneurin (DE);</li>\n      <li>Protha (TW);</li>\n      <li>Prothazin (CZ);</li>\n      <li>Prothiazine (IL);</li>\n      <li>Provita (LK);</li>\n      <li>Proz (LK);</li>\n      <li>Prromine (PH);</li>\n      <li>Pyrethia (JP);</li>\n      <li>Romergon (RO);</li>\n      <li>Sandoz Fenezal (AU);</li>\n      <li>Sylomet (PH);</li>\n      <li>Xepagan (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gyneco</i>l. 2015;126(3):e12-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunton LL, Chabner BA, Knollman BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.<i> Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/25466802 /pubmed\" target=\"_blank\" id=\"25466802 \">25466802 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice, &ldquo;Action Needed to Prevent Serious Tissue Injury With I.V. Promethazine.&rdquo; Available at http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &quot;Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2007;105(6):1615-1628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/18042859 /pubmed\" target=\"_blank\" id=\"18042859 \">18042859 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Melanson SE, Lee-Lewandrowski E, Griggs DA, Long WH, Flood JG. Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays. <i>Arch Pathol Lab Med</i>. 2006;130(12):1834-1838.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/17149959 /pubmed\" target=\"_blank\" id=\"17149959 \">17149959 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messinis IE, Souvatzoglou A, Fais N, et al, &quot;Histamine H1 Receptor Participation in the Control of Prolactin Secretion in Postpartum,&quot; <i>J Endocrinol Invest</i>, 1985, 8(2):143-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/3928731/pubmed\" target=\"_blank\" id=\"3928731\">3928731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phenadoz (promethazine) [prescribing information]. Parsippany, NJ: Watson Pharma; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phenergan (promethazine) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; November 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Potts CR and Ullery JC, &quot;Maternal and Fetal Effects of Obstetric Analgesia. Intravenous Use of Promethazine and Meperidine,&quot; <i>Am J Obstet Gynecol</i>, 1961, 81:1253-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/13737524/pubmed\" target=\"_blank\" id=\"13737524\">13737524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/25711134/pubmed\" target=\"_blank\" id=\"25711134\">25711134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Promethazine hydrochloride oral solution [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Promethazine suppositories [prescribing information]. Bronx, NY: Perrigo; August 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Promethazine tablets [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals USA Inc; November 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scadding GK, Durham SR, Mirakian R, et al; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. <i>Clin Exp Allergy</i>. 2008;38(1):19-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/18081563/pubmed\" target=\"_blank\" id=\"18081563\">18081563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eeye view. <i>Curr Drug Metab</i>. 2003;4(2):105-129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/12678691/pubmed\" target=\"_blank\" id=\"12678691\">12678691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Ardusso LR, Dimov V, et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base.<i> Int Arch Allergy Immunol</i>. 2013;162(3):193-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/24008815 /pubmed\" target=\"_blank\" id=\"24008815 \">24008815 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strenkoski-Nix LC, Ermer J, DeCleene S, et al. Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. <i>Am J Health Syst Pharm</i>. 2000;57(16):1499-1505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/ 10965395 /pubmed\" target=\"_blank\" id=\" 10965395 \"> 10965395 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI. The diagnosis and management of rhinitis: an updated practice parameter. <i>J Allergy Clin Immunol.</i> 2008;122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). 18th Expert Committee on the Selection and Use of Essential Medicines. 2011. Available at http://www.who.int/selection_medicines/committees/expert/18/applications/Promethazine/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy</i>. 2014;69(7):868-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/promethazine-pediatric-drug-information/abstract-text/24785199/pubmed\" target=\"_blank\" id=\"24785199\">24785199</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12735 Version 233.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709344\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F214081\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F214082\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061413\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061406\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F214053\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F214037\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061417\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F214074\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061416\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F214135\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F214131\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F214059\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F214041\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26080215\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F214122\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F214046\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F214049\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F214062\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10483604\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F214040\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F214058\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F214061\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038783\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12735|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=promethazine-drug-information\" class=\"drug drug_general\">Promethazine: Drug information</a></li><li><a href=\"topic.htm?path=promethazine-patient-drug-information\" class=\"drug drug_patient\">Promethazine: Patient drug information</a></li></ul></div></div>","javascript":null}